This phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD[L]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Response and survival rates in advanced stage NSCLC, unlike other cancers, rely on response to first-line therapy. Immunotherapy with PD(L)1-based therapy, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. While immunotherapy has improved survival rate, the prognosis remains poor with most patients receiving chemotherapy after immunotherapy. Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid (DNA) which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. The first part of this trial, studying samples of blood and tissue in the laboratory from patients receiving immunotherapy may help doctors learn more about the effects PD(L)1-based therapy on cells. It may also help doctors understand how well patients respond to treatment and may help develop new individualized treatment strategies. The second part of this trial also tests the effect of second-line immunotherapy, such as tremelimumab and durvalumab or adagrasib and bevacizumab, in treating patients with NSCLC with specific genetic mutations that is growing, spreading or getting worse (progressive). Tremelimumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adagrasib, a type of targeted therapy, may stop the growth of tumor cells by blocking a protein needed for tumor cell growth and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving second-line immunotherapy, tremelimumab and durvalumab or adagrasib with bevacizumab, may be safe, tolerable, and/or effective in treating patients with stage IIIB/IV NSCLC with specific genetic mutations.

开始日期2026-09-21

申办/合作机构

City of Hope National Medical Center

[+1]

NCT07122089

/ Not yet recruiting临床2期IIT

A Multicenter Open-label, Prospective Study to Evaluate the Efficacy and Safety of SIRT Using Yttrium-90 Glass Microspheres Followed by Durvalumab and Tremelimumab for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being the third leading cause of cancer-related death worldwide, with approximately 745 000 deaths reported annually.
For advanced patients, including patients with tumoral portal vein thrombosis (PVT), most treatment guidelines recommend systemic therapy, either combination immunotherapy (IO) or combination of immunotherapy and anti-angiogenic treatment for first line option.
Results for PVT patients are provided in one trial with a median overall survival of 14.2 months with IO underlying the necessity to improve treatment of PVT patients. Two recent other phase 3 trials also reported positive results for different IO regimen.
Selective internal radiation therapy (SIRT) using yttrium-90 (90Y)-loaded glass microspheres (TheraSphereTM) can be used for patients with early stage to locally advanced HCC including PVT patients without extrahepatic spread (EHS). TheraSphereTM is recognized and is reimbursed in France for PVT patients without EHS, since 2019.Several retrospective studies have shown promising results for PVT patients.
Nowadays use of SIRT in locally advanced HCC is regaining interest based on the results of the randomized DOSISPHERE-01 study including non-operable patients, about 70% with PVT. This randomized Phase II trial using 90Y-loaded microspheres sought was noted the effectiveness of 90Y-loaded microspheres using a personalized dosimetry approach versus a standard dosimetry approach.
The use of a systemic treatment as IO after a locoregional treatment with the strong local debulking effect of SIRT is logical and of interest. Indeed, the most frequent pattern of progression after SIRT is recurrence in an untreated area, including untreated liver or EHS. Patients are then usually referred to IO.
Such kind of therapeutic approach, using SIRT followed by IO has already been evaluated in a phase 2 study using nivolumab after 90Y loaded resin microspheres with promising efficacy without safety deterioration.
The aim of this study is to evaluate SIRT followed by IO used according to their current indications in advanced HCC patient with PVT patients and without EHS.

开始日期2026-01-02

申办/合作机构

Center Eugene Marquis

[+1]

NCT07175441

/ Recruiting临床2期

A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma

RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.

开始日期2026-01-01

申办/合作机构

Riboscience LLC

100 项与曲美木单抗相关的临床结果

登录后查看更多信息

100 项与曲美木单抗相关的转化医学

登录后查看更多信息

100 项与曲美木单抗相关的专利（医药）

登录后查看更多信息

587

项与曲美木单抗相关的文献（医药）

2026-02-01·ENVIRONMENTAL POLLUTION

Inhibition of human organic anion transporter 4 (OAT4) activity by bisphenol analogues

Article

作者: Fardel, Olivier ; Le Vée, Marc ; Malnoë, David ; Le Mentec, Hélène

Organic anion transporter (OAT) 4 is a kidney and placental membrane protein implicated in the transport of xenobiotics, including pollutants. The present study was designed to determine whether environmental bisphenol (BP) analogues, including emerging bisphenol A substitutes, can interact with OAT4. 6-carboxyfluorescein-related OAT4 activity displayed by OAT4-overexpressing HEK-293 cells was inhibited by 7/23 BP analogues used at 10 μM, especially by the thermal paper-contained color developer Pergafast® 201 (PF201) and the flame retardants tetrabromobisphenol A (TBBPA) and tetrachlorobisphenol A (TCBPA), acting in a concentration-dependent manner (with IC₅₀ values in the 0.95-1.48 μM range). Most of these BP analogues moreover decreased membrane transport of estrone-3-sulfate, a hormonal endogenous substrate for OAT4. Some of them, especially PF201, additionally blocked activity of the renal transporters OAT1 and OAT3. Interaction of BP analogues with OAT4 was further supported by docking simulation studies, indicating that PF201 binds to the Arg473-containing electropositive pocket of OAT4, presumed to play a key role in inhibition of OAT4-mediated transport. BP analogues however failed to trans-stimulate OAT4 activity and OAT4-overexpressing cells exhibited no or marginally increased sensitivity to PF201, TBBPA and TCBPA, thus suggesting that these BP analogues are not or poorly transported by OAT4. In vitro to in vivo extrapolation finally demonstrated that occupational exposure to PF201 is predicted to result in human OAT4 inhibition. Overall, OAT4 was demonstrated to be a target for BP analogues, including BPA substitutes, with possible deleterious consequences in terms of OAT4-mediated transport of endogenous compounds or drugs, notably for workers exposed to PF201.

2026-01-01·Journal of Clinical and Experimental Hepatology

Variceal Bleeding Due to Single-tremelimumab Regular-interval Durvalumab: Immunotherapy Induced or Cirrhosis Driven?

Letter

作者: Ankam, Vamshi K ; Priya, Srujana ; Sharma, Mithun ; Reddy, Duvvur N ; Rao, Padaki N ; Tandon, Manu ; Khan, Arif M ; Kulkarni, Anand V

2026-01-01·DRUG DISCOVERY TODAY

Integrated therapies for targeting the microenvironment of hepatocellular carcinoma

Review

作者: Cheetiyar, Anusha Lakshmi ; Bhaskar, Lvks ; Ghanta, Mohan Krishna ; Nagaraju, Ganji Purnachandra ; Karunakaran, Shriraam

Hepatocellular carcinoma (HCC) microenvironments (MEs) are composed of immune and non-immune components that drive tumor progression and treatment resistance. This narrative review summarizes recent progress in systemic therapies combined with liver-directed approaches as a new frontier in metastatic HCC treatment. Immune checkpoint inhibitors (tremelimumab and durvalumab) in combination with small- molecule agents (lenvatinib and cabozantinib) enhance T-cell activation and improve progression-free survival in HCC. Epigenetic inhibitors and RNA-based therapeutics target the HCC ME and increase the efficacy of immunotherapy. Additionally, cellular therapy targeting agents like glypican-3 (GPC3) for chimeric antigen receptor T (CAR-T) cells have shown promising results. HCC ME has distinct immune subtypes exhibiting different responses to treatments, which complicates biomarker selection and treatment timing. Personalized therapy based on ME is the future path in HCC management.

580

项与曲美木单抗相关的新闻（医药）

2026-01-08

·肿瘤界

2026 ASCO GI即将启幕！一文速览即将登场的86项中国消化肿瘤研究

点击蓝字关注我们前言 2026年美国临床肿瘤学会胃肠道肿瘤研讨会（ASCO GI）将于1月8日至10日（当地时间）在加利福尼亚州旧金山盛大召开。作为全球消化肿瘤领域的顶尖学术盛会，大会旨在为全球肿瘤学者分享前沿研究成果、交流临床实践经验，传递该领域的最新进展与发展趋势。根据已披露的摘要标题，在消化系统肿瘤领域，共有86项中国研究强势登场，广泛涵盖多个癌种。特此整理，期待与广大读者一同聆听即将响起的中国强音。胃食管癌 Oral Abstract Session 01 摘要号：282 Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial. 围手术期PD-1抗体特瑞普利单抗联合化疗对比单纯化疗治疗局部进展期胃癌或胃食管结合部癌：前瞻性、随机、II期NEOSUMMIT-01试验的3年随访结果讲者：袁庶强 | 中山大学肿瘤防治中心胃食管癌 Rapid Oral Abstract Session 01 摘要号：286 Tislelizumab plus chemoradiotherapy (CRT) versus CRT or chemotherapy (CT) as the neoadjuvant treatment for patients (pts) with locally advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A multicenter, randomized controlled, open-label, phase Ilb study (TERRIFIC). 替雷利珠单抗联合放化疗（CRT）对比CRT或化疗（CT）作为局部进展期胃/胃食管结合部腺癌（GC/GEJC）患者新辅助治疗的多中心、随机对照、开放性IIb期研究（TERRIFIC）讲者：魏嘉 | 南京鼓楼医院 02 摘要号：289 Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage I-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial. 辅助奥沙利铂联合S-1（SOX方案）对比单用S-1治疗I-III期胃或胃食管结合部腺癌患者的随机、开放标签、III期临床试验（CAPITAL研究）。讲者：聂润聪 | 中山大学肿瘤防治中心 03 摘要号：291 SOX (tegafur plus oxaliplatin) plus anti-PD-1 antibody with or without CAR-like T cell immunotherapy in the treatment of patients with previously untreated metastatic gastric cancer/gastroesophageal junction adenocarcinoma: A multicenter, open-label, randomized, controlled, phase Il trial. SOX（替吉奥联合奥沙利铂）方案联合抗PD-1抗体治疗，辅以或不辅以类CAR-T细胞免疫疗法，用于既往未经治疗的转移性胃癌/胃食管结合部腺癌患者：一项多中心、开放标签、随机对照的II期临床试验。讲者：Qin Lin | 南京鼓楼医院胃食管癌 Poster session 01 摘要号：304 Real-word treatment patterns and biomarker testing landscape of locally advanced gastric/gastroesophageal junction cancer (LA GC/GEJC) in China (SURPASS study). 中国局部晚期胃癌/胃食管交界处癌症(LAGC/GEJC)的真实世界治疗模式和生物标志物检测格局(SURPASS研究) 讲者：苏丹 | 哈尔滨医科大学附属肿瘤医院 02 摘要号：312 A cohort study of concurrent chemoradiotherapy combined with or without immune checkpoint inhibitor in locally advanced esophageal cancer. 一项关于局部晚期食管癌同步放化疗联合或不联合免疫检查点抑制剂的队列研究讲者：Yiping Lin | 南方医科大学南方医院 03 摘要号：314 Adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (RICE): A prospective, phase 2 trial. 阿得贝利单抗联合或不联合诱导化疗序贯同步放化疗治疗不可切除局部晚期食管鳞状细胞癌（RICE）：一项前瞻性II期临床试验讲者：Shuyi Wu | 中山大学肿瘤防治中心 04 摘要号：337 A novel self-controlled electroacupuncture helmet for chemotherapy-induced cognitive impairment: Results from a prospective randomized trial. 一款用于化疗所致认知障碍的新型自控电针头盔：来自前瞻性随机试验的结果。讲者：Yongling Gong | 南京市第一医院 05 摘要号：344 Neoadjuvant adebrelimab plus SOX and nab-paclitaxel in resectable locally advanced gastric and gastrosophageal junction adenocarcinoma: A multicentre, single-arm, prospective phase Il trial. 新辅助阿得贝利单抗联合SOX方案和白蛋白结合型紫杉醇治疗可切除局部晚期胃及胃食管结合部腺癌：一项多中心、单臂、前瞻性II期临床试验。讲者：Pin Liang | 大连医科大学附属第一医院 06 摘要号：348 Low-dose radiotherapy followed by chemoimmunotherapy in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma: A phase II STIMULATION-01 clinical trial. 低剂量放疗序贯化学免疫疗法用于局部晚期食管鳞状细胞癌的新辅助治疗：一项II期STIMULATION-01临床试验。讲者：Yong Yuan | 四川大学华西医院 07 摘要号：360 Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. 经匹配调整的间接比较：呋喹替尼与雷莫西尤单抗在晚期胃癌或胃食管结合部腺癌中的疗效对比。讲者：Nan An | 中山大学肿瘤防治中心 08 摘要号：364 A multicenter, randomized phase 2 study evaluating the efficacy and safety of HLX43 (an anti-PD-L1 ADC) in recurrent/metastatic esophageal squamous cell carcinoma. 一项评估HLX43（一种抗PD-L1抗体药物偶联物）在复发性/转移性食管鳞状细胞癌中疗效与安全性的多中心、随机化II期临床研究。讲者：Linlin Wang | 山东第一医科大学附属肿瘤医院 09 摘要号：368 A phase 2 study of LBL-007 (anti-LAG-3) plus tislelizumab (anti-PD-1) and chemotherapy as first-line treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma. 一项关于LBL-007（抗LAG-3抗体）联合替雷利珠单抗（抗PD-1抗体）及化疗作为不可切除局部晚期/转移性食管鳞状细胞癌患者一线治疗的II期临床研究。讲者：巴一 | 北京协和医学院 10 摘要号：369 Phase Ib/ll study of fruquintinib combined with SOX and toripalimab in advanced metastatic gastric/gastrosophageal junction adenocarcinoma (GC/GEJC). 呋喹替尼联合SOX方案及特瑞普利单抗治疗晚期转移性胃/胃食管结合部腺癌（GC/GEJC）的Ib/II期临床研究。讲者：孟祥瑞 | 郑州大学第一附属医院 11 摘要号：371 Three-year outcomes and multi-omics biomarker discovery of locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and anti-PD-1 antibody from the phase Il trial NEOCRTEC1901. 局部晚期食管鳞状细胞癌新辅助放化疗联合抗PD-1抗体治疗的三年预后及多组学生物标志物发现——来自II期临床试验NEOCRTEC1901的研究结果。讲者：Zihang Mai | 中山大学 12 摘要号：376 Preliminary results of benmelstobart (BEN) combined with concurrent chemoradiotherapy (CRT) versus CRT alone as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC): A multicentre, randomised study. 贝莫苏拜单抗（BEN）联合同步放化疗（CRT）与单纯CRT作为食管鳞状细胞癌（ESCC）新辅助治疗的初步结果：一项多中心随机研究。讲者：Han Tang | 湖北省中山医院 13 摘要号：377 Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase II trial (SYLT-023). 替雷利珠单抗联合POFI方案作为晚期胃/胃食管结合部腺癌（AGC）一线治疗：单臂、开放标签II期试验（SYLT-023）的更新数据讲者：Liyu Su | 福建省肿瘤医院 14 摘要号：382 Efficacy and safety of disitamab vedotin (RC48) in combination with sintilimab and XELOX for perioperative therapy of G/GEJ cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase Il study. 维迪西妥单抗（RC48）联合信迪利单抗及XELOX方案用于HER2过表达型胃/胃食管结合部癌围手术期治疗的疗效与安全性：一项前瞻性单臂II期研究的初步结果。讲者：Ying Liu | 郑州大学附属肿瘤医院 15 摘要号：386 Pembrolizumab in combination with chemotherapy as conversion therapy for esophageal squamous cell carcinoma with cervical lymph node metastasis: A single-center, prospective, single-arm, open-label, real-world study. 帕博利珠单抗联合化疗作为转化疗法治疗伴有颈部淋巴结转移的食管鳞状细胞癌：一项单中心、前瞻性、单臂、开放标签的真实世界研究。讲者：Qi Ding | 中国科学技术大学附属第一医院 16 摘要号：391 Clinical significance of oligometastatic esophageal squamous cell carcinoma: A retrospective cohort study. 寡转移性食管鳞状细胞癌的临床意义：一项回顾性队列研究。讲者：Tsung-Che Wu | 台湾大学医学院附属医院新竹分院 17 摘要号：395 Final results of a phase Il study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastrosophageal junction adenocarcinoma (GC/GEJC). 呋喹替尼联合信迪利单抗作为晚期胃癌及胃食管结合部腺癌（GC/GEJC）二线治疗的II期研究最终结果。讲者：Min Jin | 华中科技大学同济医学院 18 摘要号：398 Phase I trial of efficacy and safety of IMC002, a VHH-based anti-CLDN18.2 CAR-T therapy, for gastroesophageal cancers. IMC002（一种基于VHH的抗CLDN18.2 CAR-T疗法）治疗胃食管癌的I期有效性和安全性临床试验讲者：Chao Li | 中国人民解放军总医院 19 摘要号：404 Updated results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase Il clinical trial. 安罗替尼联合派安普利单抗与白蛋白结合型紫杉醇一线治疗晚期食管鳞状上皮细胞癌(ESCC)的最新研究结果：一项单臂、开放标签的II期临床试验讲者：Zhiwei Chang | 郑州大学第一附属医院 20 摘要号：406 Proximal gastrectomy versus total gastrectomy in locally advanced upper gastric cancer after neoadjuvant chemotherapy combined with tislelizumab: The preliminary results of a multicenter, prospective, randomized, phase 3 clinical trial. 新辅助化学疗法联合替雷利珠单抗治疗后，局部进展期胃上部癌行近端胃切除术与全胃切除术比较：一项多中心、前瞻性、随机、III期临床试验的初步结果讲者：王桂华 | 华中科技大学同济医学院 21 摘要号：407 Cadonilimab plus chemotherapy versus PD-1 inhibitor plus chemotherapy as first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS<5: A propensity-matched, retrospective cohort study. 卡度尼利单抗联合化疗对比PD-1抑制剂联合化疗作为PD-L1 CPS<5的晚期胃癌或胃食管结合部癌一线治疗：一项倾向匹配的回顾性队列研究讲者：Duqin Zhao | 浙江省肿瘤医院 22 摘要号：410 Adebrelimab combined with albumin-paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma: A multicenter, single-arm, phase II clinical study. 阿得贝利单抗联合白蛋白结合型紫杉醇和奈达铂作为局部晚期可切除食管鳞状细胞癌的新辅助治疗：一项多中心、单臂、II期临床研究讲者：Jianqun Ma | 哈尔滨医科大学附属肿瘤医院 23 摘要号：411 A prospective, single-arm phase Il study of trilaciclib combined with immunotherapy and chemotherapy as first-line treatment for metastatic/recurrent esophageal squamous cell carcinoma. 一项前瞻性、单臂II期研究：评估曲拉西利联合免疫治疗与化疗作为转移性/复发性食管鳞状细胞癌一线治疗方案的效果。讲者：Yi Wang | 四川省肿瘤医院 24 摘要号：412 Interim analysis of immunomodulatory low-dose radiotherapy plus chemoimmunotherapy as conversion therapy for locally advanced potentially/borderline resectable esophageal squamous cell carcinoma (ROICE trial): A phase Il single-arm study. 局部晚期潜在/临界可切除食管鳞状细胞癌转化治疗中免疫调节性低剂量放疗联合化学免疫疗法的中期分析（ROICE试验）：一项II期单臂研究讲者：任伟 | 南京鼓楼医院 25 摘要号：424 Clinical outcomes and immune contexture in SMARCA4-deficient gastric cancer patients. SMARCA4缺陷型胃癌患者的临床结局与免疫微环境讲者：Hongyong He | 复旦大学附属中山医院 26 摘要号：435 Concordance of programmed death-ligand 1 (PD-L1) status in primary esophageal squamous cell carcinoma (ESCC) and matched visceral metastases. 原发性食管鳞状细胞癌（ESCC）及其匹配内脏转移灶中程序性死亡配体1（PD-L1）状态的一致性讲者：Jhe-Cyuan Guo | 台湾大学医学院附设医院 27 摘要号：452 Non-invasive early detection of gastric cancer using red blood cell DNA genomic signature: A multi-center validation study. 利用红细胞DNA基因组特征无创早期检测胃癌：一项多中心验证研究讲者：Haobo Sun | 西湖大学胃食管癌 Trials in Progress Poster Session 01 摘要号：TPS463 SYLT-030: Efficacy and safety of tislelizumab plus mFOLFOX6 versus tislelizumab plus POF (paclitaxel + mFOLFOX6) as first-line therapy for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): A multicenter, open-label, randomized phase Ill trial. SYLT-030：替雷利珠单抗联合mFOLFOX6对比替雷利珠单抗联合POF（紫杉醇+mFOLFOX6）作为晚期胃/胃食管结合部腺癌（AGC）一线治疗的疗效与安全性：一项多中心、开放标签、随机III期临床试验。讲者：林榕波 | 福建省肿瘤医院肝胆胰肿瘤 Rapid Oral Abstract Session 01 摘要号：655 Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG). 派安普利单抗（PD-1 抑制剂）、安罗替尼（抗血管生成靶向药）、白蛋白结合型紫杉醇与吉西他滨联合作为转移性胰腺癌一线方案：一项多中心随机对照试验（RCT-PAAG）讲者：杜娟 | 南京鼓楼医院肝胆胰肿瘤 Poster session 01 摘要号：485 Combining the albumin-bilirubin (ALBI) score and ECOG performance status for enhanced prognostication in advanced biliary tract cancer treated with durvalumab-based immunochemotherapy. 联合白蛋白-胆红素（ALBI）评分与 ECOG 体能状态，优化度伐利尤单抗为基础的免疫化疗治疗晚期胆道癌的预后评估讲者：Chi-Chen Lan | 长庚纪念医院 02 摘要号：496 Pathological complete response after systemic conversion therapy and curative resection in initially unresectable hepatocellular carcinoma: Feasibility of a tumor-free for drug-free strategy. 初始不可切除肝细胞癌经全身转化治疗联合根治性切除后的病理完全缓解：“无瘤即停药” 策略的可行性讲者：王骏成 | 中山大学肿瘤防治中心 03 摘要号：499 Efficacy and safety of durvalumab plus gemcitabine/cisplatin in combined hepatocellular-cholangiocarcinoma versus cholangiocarcinoma. 度伐利尤单抗联合吉西他滨/顺铂在混合型肝细胞-胆管癌与胆管癌中的疗效与安全性讲者：Yu-Wei Hsu | 长庚纪念医院 04 摘要号：502 External validation of MAGIC-D in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy. MAGIC-D 模型在接受度伐利尤单抗联合化疗的台湾晚期胆道系统癌患者中的外部验证讲者：Chi-Lin Hsieh | 长庚纪念医院 05 摘要号：506 Transarterial chemoembolization (TACE) combined with sintilimab and bevacizumab versus TACE alone in patients with Barcelona Clinic Liver Cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis. 经动脉化疗栓塞（TACE）联合信迪利单抗与贝伐珠单抗 vs 单用 TACE 治疗巴塞罗那临床肝癌分期B期不可切除肝细胞癌：一项回顾性倾向评分匹配分析讲者：蔡鸿杰 | 中山大学附属第一医院 06 摘要号：510 Pattern of progression in advanced hepatocellular carcinoma treated with immunotherapy. 免疫治疗下晚期肝细胞癌的进展模式讲者：Thomas Yau | 香港大学 07 摘要号：511 A simple ABC score for prognosis stratification and treatment selection in advanced hepatocellular carcinoma. 用于晚期肝细胞癌预后分层与治疗选择的简易ABC评分讲者：Yung-Yeh Su | 国家卫生研究院 08 摘要号：536 Toripalimab plus hepatic artery infusion chemotherapy in hepatocellular carcinoma patients of Barcelona Clinic Liver Cancer stage C: A biomolecular exploratory, phase Il trial. 特瑞普利单抗联合肝动脉灌注化疗用于巴塞罗那临床肝癌C期肝细胞癌患者：一项生物分子探索性II期临床试验。讲者：Rongce Zhao | 中山大学肿瘤防治中心 09 摘要号：539 Optimizing the sequencing and timing of transarterial chemoembolization and systemic therapy in advanced hepatocellular carcinoma. 优化经动脉化疗栓塞与系统式治疗在晚期肝细胞癌中的序贯与时机安排。讲者：黄莹莹 | 北京医院 10 摘要号：540 Sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable HCC (START-FIT using STRIDE): A single-arm, phase Il, multi-centre study. 序贯性经动脉化疗栓塞术联合体部立体定向放射治疗，随后采用单次tremelimumab联合固定间隔durvalumab免疫疗法治疗局部晚期不可切除肝细胞癌（START-FIT方案应用STRIDE策略）：一项单臂、II期、多中心临床研究。讲者：Chi Leung Chiang | 香港大学 11 摘要号：549 Donafenib and sintilimab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A phase Il, biomarker exploratory study (Dosin TACE). 多纳非尼与信迪利单抗联合经导管动脉化疗栓塞治疗不可切除肝细胞癌：一项II期生物标志物探索性研究（Dosin TACE）。讲者：Xiaoyun Hu | 南方医科大学南方医院 12 摘要号：557 Adjuvant sintilimab plus capecitabine in resected extrahepatic cholangiocarcinoma: Interim report of a single-arm, prospective phase Il study. 辅助性信迪利单抗联合卡培他滨治疗肝外胆管癌切除术后的中期报告：一项单臂前瞻性II期研究。讲者：Jinxue Zhou | 郑州大学附属肿瘤医院 13 摘要号：564 Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase Il clinical study. 信迪利单抗联合仑伐替尼对比肝动脉灌注化疗（HAIC）用于可切除性肝细胞癌伴高复发风险患者的新辅助治疗：一项前瞻性、双臂、随机、II期临床研究。讲者：Feng Fang | 天津医科大学肿瘤医院 14 摘要号：565 Safety and efficacy of hepatic artery infusion chemotherapy (HAIC) or lenvatinib combined with sintlimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase Il clinical study. 肝动脉灌注化疗（HAIC）或仑伐替尼联合信迪利单抗作为高复发风险可切除IB期孤立性肝细胞癌新辅助治疗的安全性与有效性：一项前瞻性、随机、双队列、探索性II期临床研究。讲者：Yunlong Cui | 天津医科大学肿瘤医院 15 摘要号：569 Outcomes of sarcomatoid hepatocellular carcinoma patients treated with immunotherapy: A multi-institutional retrospective study. 肉瘤样肝细胞癌患者接受免疫治疗的疗效：一项多机构回顾性研究。讲者：Tsung-Hao Liu | 台湾大学医学院 16 摘要号：601 Early detection of hepatocellular carcinoma using red blood cell DNA signatures. 通过红细胞DNA特征早期检测肝细胞癌。讲者：XIngyun Yao | 西湖大学生命科学学院 17 摘要号：634 Real-world efficacy and safety of surufatinib in advanced neuroendocrine neoplasm. 索凡替尼在晚期神经内分泌肿瘤中的真实世界疗效与安全性。讲者：Jiang Long | 上海市第一人民医院 18 摘要号：710 Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. KRAS G12D高选择性抑制剂TSN1611在晚期实体瘤患者中的I/II期研究更新结果。讲者：Jian Li | 北京大学肿瘤医院 19 摘要号：711 Preoperative NALIRIFOX versus upfront surgery in high-risk resectable pancreatic cancer: A randomized, multi-center trial. 术前NALIRIFOX方案对比直接手术在高风险可切除胰腺癌中的疗效：一项随机多中心临床试验。讲者：Shiwei Guo | 上海长海医院 20 摘要号：718 Preliminary efficacy and biomarker analysis of CLDN18.2-targeted ADC combined with the NET inhibitor sivelestat in female patients with advanced CLDN18.2-positive pancreatic adenocarcinoma. CLDN18.2靶向抗体偶联药物联合NET抑制剂西维来司他钠治疗晚期CLDN18.2阳性胰腺癌女性患者的初步疗效与生物标志物分析。讲者：Jingrui Yan | 天津医科大学肿瘤医院 21 摘要号：719 Preliminary results of ALTER-PA-001 trial: A multicenter, open-label, randomized, phase Il trial of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer. ALTER-PA-001试验初步结果：一项多中心、开放标签、随机II期临床试验，评估安罗替尼联合贝莫苏拜单抗与AG方案对比AG方案作为转移性胰腺癌一线治疗的疗效。讲者：Jiujie Cui | 上海交通大学医学院附属仁济医院 22 摘要号：720 Efficacy and safety of liposomal irinotecan in patients with advanced pancreatic cancer: A prospective, multicenter, real-world study. 脂质体伊立替康在晚期胰腺癌患者中的疗效与安全性：一项前瞻性、多中心、真实世界研究。讲者：Jin Xu | 复旦大学附属肿瘤医院 23 摘要号：744 A real-world study of claudin 18.2 (CLDN18.2) association with molecular subtypes, mutations/biomarkers, immune landscapes, and gene signatures and prognostic value in pancreatic ductal adenocarcinoma (PDAC). 一项关于紧密连接蛋白18.2（CLDN18.2）与胰腺导管腺癌（PDAC）分子亚型、突变/生物标志物、免疫微环境、基因特征关联及其预后价值的真实世界研究。讲者：Guoqiang Zhang | 安斯泰来制药集团 24 摘要号：748 A phase 2 study of vilanterol in combination with a CLDN18.2 bispecific antibody in patients with advanced CLDN18.2-positive pancreatic ductal adenocarcinoma (PDAC). 维兰特罗联合Claudin18.2双特异性抗体治疗晚期Claudin18.2阳性胰腺导管腺癌（PDAC）的II期研究讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院 25 摘要号：749 A phase 2 study of STING agonist ADU-S100 combined with a CLDN18.2 bispecific antibody in patients with advanced pancreatic cancer. STING激动剂ADU-S100联合CLDN18.2双特异性抗体治疗晚期胰腺癌的II期研究讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院 26 摘要号：750 Predictive value of CLDN18.2+CD8+ T cells in peripheral blood and tumor tissue for immunotherapy response and survival in gastric and pancreatic cancers. 外周血和肿瘤组织中CLDN18.2+CD8+ T细胞对胃癌和胰腺癌免疫治疗反应及生存情况的预测价值讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院 27 摘要号：751 Multicenter prospective validation of PanClaudinAI: An AI for predicting Claudin 18.2 from CT in pancreatic cancer. PanClaudinAI的多中心前瞻性验证：一种基于CT预测胰腺癌中Claudin 18.2的人工智能讲者：Tianxing Zhou | 天津医科大学附属肿瘤医院肝胆胰肿瘤 Trials in Progress Poster Session 01 摘要号：TPS607 Curative therapy after atezolizumab and bevacizumab treatment for unresectable hepatocellular carcinoma: A multinational retrospective study. 阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌后的根治性治疗：一项多国回顾性研究。讲者：Yu-Yun Shao | 台湾大学医学院附设医院结直肠癌 Oral Abstract Session 01 摘要号：477 Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study. 帕博利珠单抗辅助治疗经手术切除或局部消融后获得完全影像学缓解的肝细胞癌患者：III期 KEYNOTE-937 研究讲者：陈林 | 香港中文大学结直肠癌 Poster session 01 摘要号：21 Validation of CanCatch Surf assay for tissue-agnostic detection of minimal residual disease in colorectal cancer. CanCatch Surf 检测方法在结直肠癌中泛组织微小残留病检测的验证研究讲者：Shaoyong Dong | 河北大学附属医院 02 摘要号：53 Efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX or FOLFIRI plus drug-eluting bead transarterial chemoembolization in unresectable colorectal liver metastases. FOLFOX或FOLFIRI方案肝动脉灌注化疗联合载药微球经动脉化疗栓塞治疗不可切除结直肠癌肝转移的疗效与安全性讲者：刘宝将 | 北京大学肿瘤医院 03 摘要号：71 Anastomotic leak and oncologic outcomes after colorectal cancer resection: A real-world analysis. 结直肠癌切除术后吻合口瘘与肿瘤学结局的真实世界分析讲者：Tina T. Lin | 中山医学大学 04 摘要号：118 EMB-01, a tetravalent anti-EGFR/cMET bispecific antibody, in the left-sided, RAS/BRAF wild-type, late-line metastatic colorectal cancer: Subgroup analysis of baseline characteristics and response from a phase 1/2 study. 四价抗EGFR/cMET双特异性抗体EMB-01用于左侧、RAS/BRAF野生型后线转移性结直肠癌：1/2期研究中基线特征与疗效的亚组分析讲者：李健 | 北京大学肿瘤医院 05 摘要号：119 Neoadjuvant chemotherapy and serplulimab in MSS/pMMR locally advanced rectal cancer (FIRM): A phase II trial. 新辅助化疗联合斯鲁利单抗用于MSS/pMMR局部晚期直肠癌（FIRM 研究）：一项II期临床试验讲者：吴庭玉 | 上海交通大学医学院附属新华医院 06 摘要号：121 Cadonilimab combined with FOLFIRINOX and bevacizumab as first-line treatment for microsatellite stable/proficient mismatch repair metastatic colorectal cancer: Updated survival analysis and safety outcomes from a multicenter, single-arm, phase 2 study (SYLT-026). 卡度尼利单抗联合FOLFIRINOX方案与贝伐珠单抗作为微卫星稳定/错配修复功能正常转移性结直肠癌的一线治疗：一项多中心单臂II期研究（SYLT-026）的生存分析更新及安全性结局讲者：Yi Yin | 福建省肿瘤医院 07 摘要号：124 Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study. 西妥昔单抗（Q3W）联合卡培他滨作为KRAS/BRAF野生型转移性结直肠癌一线维持治疗的疗效与安全性：一项Ib期剂量递增研究讲者：谢晓煜 | 中山大学附属第六医院 08 摘要号：128 Short-course radiotherapy (SCRT) followed by immunochemotherapy plus fruquintinib as the total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT). 短程放疗联合免疫化疗加呋喹替尼作为局部晚期直肠癌的全程新辅助治疗（TNT）：一项多中心、单臂、开放标签的II期研究（UNION TNT）讲者：张涛 | 华中科技大学同济医学院附属协和医院 09 摘要号：131 Progression-free survival with the ICE regimen in refractory RAS/BRAF wild-type and MSS mCRC patients. ICE方案用于难治性RAS/BRAF野生型及微卫星稳定转移性结直肠癌患者的无进展生存期讲者：黄莹莹 | 北京医院 10 摘要号：145 Surgical efficacy of neoadjuvant mono-immunotherapy for T₄-deficient mismatch repair colon cancer: A prospective, single-arm, phase II trial. 新辅助单药免疫治疗用于T₄期错配修复缺陷型结肠癌的手术疗效：一项前瞻性、单臂II期试验讲者：孙振 | 北京协和医院 11 摘要号：147 Neoadjuvant short-course radiotherapy combined with CAPOX and PD-1 inhibitor for MSS/pMMR high-risk locally advanced colon cancer: A randomized, prospective, multicentre, phase II trial (TORCH-C). 新辅助短程放疗联合CAPOX方案与PD-1抑制剂用于MSS/pMMR 高危局部晚期结肠癌：一项随机、前瞻性、多中心II期试验（TORCH-C）讲者：张慧 | 复旦大学附属肿瘤医院 12 摘要号：148 Second-line Irinotecan followed by third-line cetuximab plus irinotecan versus second-line cetuximab combined with irinotecan in treatment of oxaliplatin/5-FU failure RAS/RAF wild-type mCRC patients: A randomized phase II study. 奥沙利铂/5-氟尿嘧啶治疗失败的RAS/RAF野生型转移性结直肠癌患者中，二线伊立替康序贯三线西妥昔单抗联合伊立替康 vs 二线西妥昔单抗联合伊立替康的对比：一项随机II期研究讲者：李文桦 | 复旦大学附属肿瘤医院 13 摘要号：154 Circulating tumor DNA to guide rechallenge with cetuximab plus irinotecan in Chinese RAS/BRAF wild type metastatic colorectal cancer: A phase II trial. 循环肿瘤DNA指导西妥昔单抗联合伊立替康在国内RAS/BRAF野生型转移性结直肠癌中的再挑战治疗：一项II期试验讲者：李宇红 | 中山大学肿瘤防治中心 14 摘要号：157 Regorafenib combined with trifluridine/tipiracil versus regorafenib monotherapy in refractory metastatic colorectal cancer (FDZL-REGOT): A randomized phase 2 trial. 瑞戈非尼联合曲氟尿苷/替匹嘧啶 vs 瑞戈非尼单药治疗难治性转移性结直肠癌（FDZL-REGOT 研究）：一项随机II期试验讲者：王辰辰 | 复旦大学附属肿瘤医院 15 摘要号：173 Sequencing fruquintinib and trifluridine/tipiracil to improve outcomes in the real-world management of MMR-proficient, chemo-refractory colorectal cancer in Hong Kong. 香港地区错配修复功能正常、化疗难治性结直肠癌的真实世界管理中，呋喹替尼与曲氟尿苷/替匹嘧啶的序贯治疗以改善结局讲者：Jenny Lo | 香港大学 16 摘要号：184 Efficacy and safety of pralsetinib in RET fusion-positive solid tumors: Data from the TAPISTRY trial. 普拉替尼在RET融合阳性实体瘤中的疗效与安全性：来自TAPISTRY试验的数据讲者：Chia-Chi Lin | 台湾大学 17 摘要号：188 Influence of the NECTIN2-TIGIT axis on resistance to PD-L1 blockade combined with chemoradiotherapy in MSS locally advanced rectal cancer. NECTIN2-TIGIT轴对微卫星稳定型局部晚期直肠癌中PD-L1抑制剂联合放化疗耐药性的影响讲者：Zhehui Zhu | 复旦大学附属中山医院 18 摘要号：206 Multi-omics characterization of response to tyrosine kinase inhibitor plus immunotherapy in MSS/pMMR metastatic colorectal cancer: A multicenter biomarker study. 微卫星稳定/错配修复功能正常转移性结直肠癌中酪氨酸激酶抑制剂联合免疫治疗应答的多组学特征分析：一项多中心生物标志物研究讲者：Zhihao Hu | 陆军军医大学 19 摘要号：299 Single-cell sequencing to reveal immune features of treatment response to neoadjuvant chemoradiotherapy plus immunotherapy in locally advanced rectal cancer. 单细胞测序揭示局部晚期直肠癌中新辅助放化疗联合免疫治疗应答的免疫特征讲者：Qianyu Wang | 中国人民解放军总医院 20 摘要号：230 Influence of multiomics on tumor microenvironment remodeling in locally advanced rectal cancer following neoadjuvant chemoradiotherapy plus immunotherapy. 多组学对局部晚期直肠癌新辅助放化疗联合免疫治疗后肿瘤微环境重塑的影响讲者：Na Tian | 中国人民解放军总医院结直肠癌 Trials in Progress Poster Session 01 摘要号：TPS258 Phase II trial of neoadjuvant short-course radiotherapy followed by ivonescimab with or without chemotherapy in locally advanced rectal cancer (TRIUNITE-03). 局部晚期直肠癌中新辅助短程放疗序贯依沃西单抗联合或不联合化疗的II期试验（TRIUNITE-03 研究）讲者：Haode Shen | 陆军军医大学陆军特色医学中心 (大坪医院) 02 摘要号：TPS261 TRIUNITE-02: A phase 2, open-label, randomized study of neoadjuvant CAPEOX plus tislelizumab and chidamide versus CAPEOX alone in previously untreated, resectable, locally advanced mismatch repair-proficient/microsatellite stable colon cancer. TRIUNITE-02研究：未接受过治疗、可切除的局部晚期错配修复功能正常/微卫星稳定型结肠癌中，新辅助CAPEOX方案联合替雷利珠单抗与西达本胺 vs 单用 CAPEOX 的II期开放标签随机研究讲者：Zhuo Chen | 陆军军医大学陆军特色医学中心 (大坪医院) 03 摘要号：TPS271 Reducing the resection range after neoadjuvant therapy for locally advanced upper rectal and rectosigmoid junction cancers (RESET): A prospective, multicenter, randomized controlled phase 3 study. 局部晚期高位直肠癌与直肠乙状结肠交界处癌新辅助治疗后缩小切除范围（RESET 研究）：一项前瞻性、多中心、随机对照III期研究讲者：Zhiming Liu | 中山大学附属第六医院 04 摘要号：TPS272 Phase II trial of neoadjuvant short-course radiotherapy followed by ivonescimab with or without chemotherapy in locally advanced rectal cancer (TRIUNITE-03). 局部晚期直肠癌中新辅助短程放疗序贯依沃西单抗联合或不联合化疗的II期试验（TRIUNITE-03 研究）讲者：Haode Shen | 陆军军医大学陆军特色医学中心 (大坪医院) 备注：排名不分先后，按照摘要号进行排序如有遗漏或任何问题，请给我们留言~ 声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：医脉通消化系统肿瘤编辑：Lagertha 审核：素问

免疫疗法ASCO会议临床2期细胞疗法临床结果

2026-01-08

·今日头条

制药巨头的冰与火之歌：阿斯利康 540 亿营收背后的荣耀与暗礁

阿斯利康是全球顶尖生物制药企业，稳居全球药企营收前十行列，在心血管、代谢、肿瘤、呼吸等多个治疗领域具备强大竞争力，其中肿瘤业务已成为第一大营收板块（2025年上半年占比43%）。同时，凭借深度本土化布局，公司成为中国市场最具影响力的外资药企之一，也是中英经贸合作与地方产业生态构建的核心参与者。一、发展史：从跨国合并到全球化创新药企阿斯利康（AstraZeneca Plc）的发展历程核心围绕“跨国整合+本土化深耕”双主线展开，既经历过专利悬崖与并购危机的至暗时刻，也凭借战略变革实现逆袭，最终形成覆盖研发、生产、销售的全产业链全球化布局，其中中国市场的战略布局成为其发展关键支点。从全球根源来看，阿斯利康由瑞典阿斯特拉公司与英国捷利康公司于1999年合并组建，合并后开启全球化扩张之路，而2012-2022年的十年战略变革则成为其重塑行业地位的关键转折。 1993年，阿斯利康前身阿斯特拉公司进入中国，在无锡高新区设立企业，成为无锡最早的外资企业之一，开启了在华发展的序幕。2001年，阿斯利康制药有限公司在无锡的新工厂正式启用，这是其在中国的首个生产基地，后续逐步发展为亚太地区最大的包装和生产供应基地。2007年，阿斯利康进一步深化在华布局，在无锡设立中国区销售总部——阿斯利康（无锡）贸易有限公司，成为全国首家获得药品贸易资质（GSP）的外资药企，构建起“生产+销售”的核心架构。全球层面，阿斯利康的发展轨迹呈现“危机-变革-跃升”的鲜明特征。2012年前后，公司陷入至暗时刻：核心产品如降胆固醇药物Crestor、抗胃酸反流药物Nexium等专利陆续到期，面临巨额营收缺口，且研发投入不足、研发成功率仅4%（远低于行业平均），市值管理优先于研发的策略导致管线青黄不接。 2012年Pascal Soriot出任CEO后开启大刀阔斧改革，核心举措包括：大幅提升研发投入（研发费用率从2010年的16%提升至2022年的22%）、聚焦肿瘤与罕见病等核心赛道、推行“五R框架”（正确目标、患者群体、身体组织、安全制度、商业机会）提升研发效率，同时通过战略合作与并购补全管线——如69亿美元引进与第一三共联合开发的ADC药物德曲妥珠单抗（Enhertu），重启此前被放弃的奥拉帕尼研发并打造为重磅产品（2022年销售额26亿美元）。系列变革推动公司研发成功率提升至20%（行业平均3倍），2022年营收达443.5亿美元，提早兑现业绩承诺，2024年全球营收进一步增至540.73亿美元，实现从危机边缘到行业领军者的逆袭。目前，公司在慢病管理、肿瘤治疗等核心领域形成多元化产品矩阵，与第一三共联合开发的Trop2靶向ADC疗法等多款创新药处于上市申请阶段，管线储备充足。二、行业地位：全球顶尖生物制药企业，中国市场核心支柱 1. 全球市场影响力突出：2024年全球营收达540.73亿美元，同比增长21%，展现强劲增长势头。核心产品矩阵优势显著，肿瘤领域的度伐利尤单抗（Imfinzi）2024年销售额47.17亿美元，同比增长21%；合作开发的德曲妥珠单抗（Enhertu）2025年一季度全球销售额达10.86亿美元，同比大幅增长，成为关键增长引擎。在慢病管理领域，构建了覆盖心血管、肾脏及代谢、呼吸等领域的立体化产品布局，拥有10余款创新药物，且有超过40个新产品及新适应症在研，未来增长潜力充足。 2. 中国市场战略地位核心：中国区是阿斯利康全球关键市场，2024年中国区收入创历史新高，达64.13亿美元；2025年一季度中国市场营收18.05亿美元，同比增长5%，占全球市场份额的13%。在华产品覆盖广泛，无锡生产基地的产品供应全球约70个市场的20多个品牌，包括心血管药倍他乐克缓释片、降糖药安达唐、抗肿瘤药泰瑞沙等知名产品。同时，阿斯利康深度参与中国医疗健康生态建设，其打造的诊疗创新全病程解决方案已落地全国数千家医院，并走向全球多个国家，成为中英经贸合作的典范。此外，通过与中国石药集团等本土企业合作，共同开发慢性病潜力药物，进一步深化本土化创新布局。 3. 产业生态引领作用显著：作为无锡生物医药产业的“链主企业”，阿斯利康带动当地集聚2400余家产业链企业，构建起完整的生物医药产业生态，无锡高新区生物医药产业规模突破千亿元，占全市比重超50%，其投资项目持续为地方产业发展注入强劲动力。三、面临挑战：合规风险与市场竞争双重压力尽管阿斯利康业绩增长强劲、行业地位稳固，但当前仍面临一系列挑战，核心集中在合规风险暴露与全球医药市场竞争加剧两大层面。 1. 中国市场合规风险集中爆发：2024年以来，阿斯利康在中国陷入多起合规风波。2024年7月，公司证实部分员工因数据隐私泄露和进口未经许可药品被拘留；10月，全球执行副总裁、国际业务主席及中国总裁王磊被通报配合调查，后续被证实拘留，调查涉及医疗保险欺诈、非法药品进口和个人信息泄露等多项指控。2025年，合规风险进一步升级，1月收到深圳海关《移送审查起诉告知书》，涉嫌偷逃进口税款90万美元（涉及度伐利尤单抗、替西木单抗两款抗肿瘤药物），若判定违法最高面临450万美元罚款；4月又收到新的《鉴定意见通知书》，涉嫌偷逃德曲妥珠单抗进口税款160余万美元，最高或面临800万美元罚款。系列合规风波不仅可能带来大额经济损失，还对其在中国市场的品牌声誉与业务开展造成负面影响。 2. 全球医药市场竞争加剧：全球生物制药领域创新迭代加速，同靶点药物同质化竞争激烈。在肿瘤、慢病等核心领域，阿斯利康面临来自葛兰素史克、诺华等国际药企的竞争压力。同时，中国本土制药企业崛起，恒瑞医药等本土龙头通过自主研发与国际合作不断突破，改变全球竞争格局，阿斯利康在华市场面临本土企业的直接竞争。此外，全球医药政策调整，包括药品集中采购、医保控费等措施，也对其产品定价与利润空间形成挤压。 3. 研发与全球化运营压力升级：一方面，创新药企的核心竞争力依赖持续高额研发投入，阿斯利康虽通过改革提升了研发效率，但研发失败风险与成本压力始终存在，维持管线竞争力的投入强度不可降低。另一方面，全球化布局面临多区域政策与投资环境变化的挑战：2025年公司两度撤回在英国的重大投资计划（包括剑桥研发基地2亿英镑投资、北部疫苗厂4.5亿英镑投资），理由是英国政府对生命科学产业投资不足、低估创新药物价值，反映出核心市场投资环境波动对其全球化布局的冲击。此外，不同国家和地区的监管体系差异、合规要求提升，进一步增加了运营管理的复杂度与成本，对其全球化协同运营能力提出更高要求。

2026-01-07

·中国临床试验注册中心

特瑞普利单抗联合妥拉美替尼和西妥昔单抗β后线治疗晚期结直肠癌的探索性临床研究

注册号： Registration number： ChiCTR2600116223 最近更新日期： Date of Last Refreshed on： 2026-01-07 09:02:13 注册时间： Date of Registration： 2026-01-07 00:00:00 注册号状态：补注册Registration Status： Retrospective registration注册题目：特瑞普利单抗联合妥拉美替尼和西妥昔单抗β后线治疗晚期结直肠癌的探索性临床研究Public title： Exploratory clinical study of late-stage colorectal cancer treated with the combination of durvalumab, cetuximab, and β-blockers注册题目简写：English Acronym：研究课题的正式科学名称：特瑞普利单抗联合妥拉美替尼和西妥昔单抗β后线治疗晚期结直肠癌的探索性临床研究Scientific title： Exploratory clinical study of late-stage colorectal cancer treated with the combination of durvalumab, cetuximab, and β-blockers研究课题代号(代码)： Study subject ID：在二级注册机构或其它机构的注册号： The registration number of the Partner Registry or other register：申请注册联系人：权明研究负责人：高勇 Applicant： Ming Quan Study leader： Yong Gao 申请注册联系人电话： Applicant telephone： +86 139 1631 5186 研究负责人电话： Study leader's telephone： +86 133 1016 7477申请注册联系人传真： Applicant Fax：研究负责人传真： Study leader's fax：申请注册联系人电子邮件： Applicant E-mail： mquan@tongji.edu.cn 研究负责人电子邮件： Study leader's E-mail： drgaoyong@tongji.edu.cn申请单位网址(自愿提供)： Applicant website(voluntary supply)：研究负责人网址(自愿提供)： Study leader's website(voluntary supply)：申请注册联系人通讯地址：上海市浦东新区云台路1800号研究负责人通讯地址：上海市浦东新区云台路1800号Applicant address： 1800 Yuntai Road, Pudong New Area, Shanghai Study leader's address： 1800 Yuntai Road, Pudong New Area, Shanghai申请注册联系人邮政编码： Applicant postcode：研究负责人邮政编码： Study leader's postcode：申请人所在单位：上海市东方医院Applicant's institution： Shanghai East Hospital研究负责人所在单位：上海市东方医院Affiliation of the Leader： Shanghai East Hospital是否获伦理委员会批准：是Approved by ethic committee： Yes伦理委员会批件文号： Approved No. of ethic committee： [2025]研审第(124)号伦理委员会批件附件： Approved file of Ethical Committee：查看附件View批准本研究的伦理委员会名称：上海市东方医院医学伦理委员会Name of the ethic committee： Ethics Committee of Shanghai East Hospital伦理委员会批准日期： Date of approved by ethic committee： 2025-05-22 00:00:00伦理委员会联系人：鲍思慰Contact Name of the ethic committee： Siwei Bao伦理委员会联系地址：上海市浦东新区云台路1800号Contact Address of the ethic committee： 1800 Yuntai Road, Pudong New Area, Shanghai伦理委员会联系人电话： Contact phone of the ethic committee： +86 21 3880 4518 伦理委员会联系人邮箱： Contact email of the ethic committee：研究实施负责（组长）单位：上海市东方医院Primary sponsor： Shanghai East Hospital研究实施负责（组长）单位地址：上海市浦东新区云台路1800号Primary sponsor's address： 1800 Yuntai Road, Pudong New Area, Shanghai试验主办单位(项目批准或申办者)： Secondary sponsor：国家：中国省(直辖市)：上海市(区县)： Country： China Province： Shanghai City：单位(医院)：上海市东方医院具体地址：上海市浦东新区云台路1800号 Institution hospital： Shanghai East Hospital Address： 1800 Yuntai Road, Pudong New Area, Shanghai经费或物资来源：上海君实生物医药科技有限公司Source(s) of funding： Shanghai Junshi Biosciences Co., Ltd.研究疾病：消化道肿瘤 Target disease： Gastrointestinal tumors研究疾病代码：Target disease code：研究类型：干预性研究Study type： Interventional study研究所处阶段：上市后药物 Study phase： 4研究设计：单臂 Study design： Single arm 研究目的：评价特瑞普利单抗联合妥拉美替尼和西妥昔单抗β后线治疗晚期结直肠癌的初步疗效和安全性。 Objectives of Study： Evaluation of the combination of Tremelimumab with Tolaram and Cetuximab as a second-line treatment Preliminary efficacy and safety of advanced colorectal cancer.药物成份或治疗方案详述： Description for medicine or protocol of treatment in detail：纳入标准： 1.18-80 岁（包括 18 岁及 80 岁）； 2. ECOG 评分 0-1 分； 3. 经组织学确诊为晚期或转移性结直肠癌，且至少有一个可测量病灶（研究者根据 RECIST1.1 评估）； 4. 接受过 2 线标准化疗方案，且有影像学证据证明疾病进展；对于新辅助或辅助治疗（化疗或化放疗），如果在治疗期间或停止治疗后 6 个月内发生疾病进展，应将其算作一线治疗（研究者根据 RECIST1.1 评估）；或对标准治疗方案不耐受的患者； 5. 预期生存期＞12 周； 6. 主要脏器功能及骨髓功能正常，满足以下要求： a. 血红蛋白≥90g/L；（14 天内未输血） b. 中性粒细胞绝对计数≥1.5×109/L c. 血小板计数≥100×109/L d. 总胆红素≤1.5 倍正常值上限（ULN） e. 谷丙转氨酶(ALT)和谷草转氨酶(AST)≤2.5 倍 ULN；如存在肝脏转移，则 ALT和 AST≤5 倍 ULN f. 肌酐≤1.5 倍 ULN g. 左心室射血分数（left ventricular ejection fraction，LVEF）≥50%；QTc 男性＜450ms，女性＜470ms 7. 未曾接受抗凝治疗的患者凝血酶原时间国际标准化比值（INR）≤1.5，部分凝血活酶时间（APTT）≤1.5 倍 ULN。接受全量或胃肠外抗凝药物治疗的患者需要在进入临床研究前抗凝药物的剂量稳定至少 2 周，并且凝血检测试验的结果在当地治疗所限制的范围以内； 8. 接受前期治疗的毒性在入组前已恢复至 CTCAE 标准≤1 级（如有手术，伤口已完全愈合）； 9. 育龄妇女须在入组前 14 天内进行妊娠试验（血清或尿液）结果为阴性，且自愿在观察期间和末次给予研究药物后 3 个月内采用适当的方法避孕，且须为非哺乳期；男性受试者应为手术绝育或同意在观察期间和末次给予研究药物后 3 个月内采用适当方法避孕； 10. 患者自愿参加并签署知情同意书，预计依从性好，能按方案要求配合研究；Inclusion criteria 1.18-80 years old (including 18 and 80 years old); 2. ECOG score of 0-1; 3. Histologically confirmed advanced or metastatic colorectal cancer with at least one measurable lesion (investigator according to RECIST1.1 evaluation); 4. Received 2-line standard chemotherapy regimen, and there is imaging evidence of disease progression; for neoadjuvant or adjuvant therapy (chemotherapy or chemoradiotherapy), if the disease occurs during treatment or within 6 months after stopping treatment progress should be considered as first-line treatment (as assessed by the investigator according to RECIST 1.1); or standard treatment has been discontinued due to disease progression patients with intolerance to the case; 5. Expected survival period > 12 weeks; 6. The main organ function and bone marrow function are normal, meeting the following requirements: Hemoglobin >=90g/L; (no blood transfusion within 14 days); Neutrophil absolute count >=1.5×10^9/L; Platelet count >=100×10^9/L; Total bilirubin <=1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are <=2.5 times the upper limit of normal (ULN); if there is liver metastasis, ALT levels should be monitored and AST<=5 times ULN; Creatinine <=1.5 times ULN; Left ventricular ejection fraction (LVEF) >=50%; QTc male < 450ms, Female < 470ms 7. For patients who have not received anticoagulant therapy, their international normalized ratio (INR) of prothrombin time is <=1.5, and some coagulation factors are normal activated Partial Thromboplastin Time (APTT) <=1.5 times ULN. Patients receiving full-dose or parenteral anticoagulant therapy are required to the dose of anticoagulant drugs should be stable for at least 2 weeks before entering clinical research, and the results of coagulation testing should be within the limits of local treatment; 8. The toxicity from previous treatment has been restored to CTCAE standard <= Grade 1 before enrollment (if there is surgery, the wound has been complete healing); 9. Women of childbearing age must undergo a pregnancy test (serum or urine) within 14 days before enrollment, with negative results, and have not had sexual intercourse since willing to use appropriate contraception during the observation period and for 3 months after the last administration of the study drug, and must be non-lactating; male subjects should be surgically sterilized or agree to be observed during and after the last administration of study medication use appropriate contraception for the next 3 months; 10. The patient voluntarily participates and signs the informed consent form, with good compliance expected and ability to cooperate with the study according to the protocol requirements.排除标准： 1.入组前 4 周内进行包括放疗、化疗（静脉）、靶向治疗及免疫治疗等抗肿瘤治疗，或参与另一项干预性临床试验；入组前 2 周内口服化疗药物或靶向药物； 2. 入组前 30 天内仍存在其他尚需接受治疗的恶性肿瘤； 3. 即使经过药物治疗，高血压仍然控制不良（收缩压持续升高≥150mmHg 或舒张压≥100mmHg） 4. 患有未能控制的心脏临床症状或疾病，如（1）NYHA II 级及以上心力衰竭（2）不稳定型心绞痛（3）1 年内发生过心肌梗死（4）有临床意义的室上性或室性心律失常需要临床干预的患者； 5. 3 个月内发生过活动性出血；6 个月内发生过动脉/静脉血栓事件；存在遗传性或获得性出血(如凝血功能障碍)或血栓倾向；目前正在使用或最近正在进行(研究治疗开始前 10 天)用于治疗目的的全剂量口服或注射抗凝或溶栓药物；研究前 4 周内进行过手术(活检除外)或手术切口未完全愈合；目前或最近正在使用(研究前 10 天)阿司匹林(>325 mg/天)或双嘧达莫、噻氯匹啶、氯吡格雷和西洛他唑； 6. 治疗前 2 周内使用全身皮质激素或其他全身免疫抑制药物。在试验期间开始或预计需要使用免疫抑制药物(允许吸入糖皮质激素，糖皮质激素的生理替代剂量)； 7. 有免疫缺陷病史，包括 HIV 血清检测阳性，其他获得性、先天性免疫缺陷疾病，或有器官移植史； 8. 存在活动性乙型肝炎（HBeAg 阳性且 HBV DNA≥500 IU/mL）、丙型肝炎（丙肝抗体阳性且 HCV RNA 高于分析方法检测下限）； 9. 需要抗生素、抗病毒药或抗真菌药控制的严重感染者； 10. 既往或目前存在 CK 升高相关的神经肌肉类疾病（例如炎症性肌病、肌营养不良、肌萎缩性侧索硬化、脊髓性肌萎缩症、横纹肌溶解综合征）； 11. 治疗开始前 7 天内，或研究期间需要使用影响细胞色素 P450（CYP）酶活性者，如 CYP2C9、CYP3A4 的强诱导剂、强抑制剂，正在服用经 CYP1A2 代谢的治疗窗较窄的药物； 12. 已知对本试验药物中任何成分过敏者； 13. 既往有明确的神经或精神障碍史，包括癫痫和痴呆 14. 已知无法控制的或有症状的活动性中枢神经系统（CNS）转移，表现为出现临床症状、脑水肿、脊髓压迫、癌性脑膜炎、软脑膜疾病和/或进展性生长。 15. 无法吞咽研究药物的患者，存在慢性腹泻（包括但不限于肠易激综合症，Crohn's 病，溃疡性结肠炎）和肠梗阻等影响药物服用和吸收的多种因素； 16. 研究者认为不适合纳入的其他情况。如伴有家庭或社会等因素，会影响到受试者的安全，或资料及样品的收集。Exclusion criteria： 1. Anti-tumor treatment including radiotherapy, chemotherapy (intravenous), targeted therapy, and immunotherapy within 4 weeks before enrollment, or participation in another interventional clinical trial; Oral chemotherapy drugs or targeted drugs within 2 weeks prior to enrollment; 2. Other malignant tumors that still need to be treated within 30 days before enrollment; 3. Poorly controlled hypertension (persistently elevated systolic blood pressure >=150 mmHg or diastolic blood >=100 mmHg) even with medication) 4. Patients with uncontrolled cardiac clinical symptoms or diseases, such as (1) NYHA class II and above heart failure, (2) unstable angina, (3) myocardial infarction within 1 year, (4) clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention; 5. Active bleeding within 3 months; Arterial/venous thrombotic events within 6 months; Presence of hereditary or acquired bleeding (eg, coagulation dysfunction) or thrombophilia; Currently using or recently undergoing (10 days prior to initiation of study treatment) full-dose oral or injectable anticoagulant or thrombolytic agents for therapeutic purposes; Surgery (other than biopsy) or surgical incision not fully healed within 4 weeks prior to the study; Current or recent use (10 days prior to the study) of aspirin (>325 mg/day) or dipyridamole, ticlopidine, clopidogrel, and cilostazol; 6. Use of systemic corticosteroids or other systemic immunosuppressive drugs within 2 weeks prior to treatment. Initiation or anticipated need for immunosuppressive medications during the trial period (inhaled glucocorticoids, physiologic replacement doses of glucocorticoids are allowed); 7. History of immunodeficiency, including positive HIV serotest, other acquired, congenital immunodeficiency diseases, or history of organ transplantation; 8. Active hepatitis B (HBeAg positive and HBV DNA>=500 IU/mL), hepatitis C (hepatitis C antibody positive and HCV RNA higher than the lower limit of detection of the analytical method); 9. Severe infections requiring antibiotics, antivirals, or antifungal control; 10. Previous or current neuromuscular diseases associated with elevated CK (e.g., inflammatory myopathy, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy, rhabdomyolytic syndrome); 11. Within 7 days before the start of treatment, or during the study, those who need to use cytochrome P450 (CYP) enzyme activity, such as strong inducers and inhibitors of CYP2C9 and CYP3A4, are taking drugs with a narrow treatment window metabolized by CYP1A2; 12. Known allergy to any component of this test drug; 13. Prior history of definite neurological or psychiatric disorders, including epilepsy and dementia 14. Known uncontrollable or symptomatic active central nervous system (CNS) metastases as present Clinical signs, cerebral edema, spinal cord compression, carcinomatous meningitis, leptomeningeal disease, and/or progressive growth. 15. Patients who are unable to swallow the study drug, with chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction and other factors that affect drug intake and absorption; 16. Other conditions that the investigator deems unsuitable for inclusion. If accompanied by family or social factors, it will affect the safety of the subject, or the collection of data and samples.研究实施时间： Study execute time：从 From 2025-05-01 00:00:00至 To 2026-05-31 00:00:00 征募观察对象时间： Recruiting time：从 From 2025-10-10 00:00:00 至 To 2026-05-31 00:00:00干预措施： Interventions：组别：结直肠癌样本量： 59 Group： Colorectal cancer Sample size：干预措施：妥拉美替尼：固定剂量 9mg（必要时减量为 6mg），口服，每日 2 次（隔天服药），空腹或与低脂饮食同时服用（每日服药的时间应尽可能相同），以温开水送服；2 周为一个周期；西妥昔单抗β注射液：在首次滴注本品之前至少 1 小时，患者必须接受抗组胺药物和皮质类固醇类药物的预防用药。建议在后续治疗中，每次使用本品前都给予患者上述预防用药。本品每 2 周给药一次。按体表面积为 500mg/m2。初始给药建议 120 分钟以上完成滴注，总输注时间不超过 240 分钟。如果首次给药耐受良好，后续给药的单次滴注时间为 60 分钟以上，总输注时间不超过 240 分钟。；特瑞普利单抗：每周期第 1 天 80mg/kg 静脉滴注，2 周为一个周期。建议每次输注时间超过 30-60 分钟。干预措施代码： Intervention： Tolametini: Fixed dose 9mg (reduced to 6mg if necessary), taken orally, twice daily (administered every other day), Take it on an empty stomach or with a low-fat diet (the time of taking the medicine should be as consistent as possible each day), and consume it with warm water; for 2 weeks for one cycle; Cetuximab β Injection: Patients must receive an antihistamine at least 1 hour before the first infusion of this product Preventive medication for allergens and corticosteroids. It is recommended that patients be given this medication before each use during subsequent treatment The aforementioned prophylactic medication is administered once every 2 weeks. Based on a body surface area of 500mg/m2, the recommended initial dosage is 120mg Complete the drip infusion for more than 15 minutes, with a total infusion time not exceeding 240 minutes. If the initial administration is well tolerated, subsequent administrations can be given The single infusion time for is more than 60 minutes, and the total infusion time does not exceed 240 minutes.; Tremelimumab: 80mg/kg intravenous infusion on day 1 of each cycle, with 2 weeks as one cycle. It is recommended to infuse each time Note: The duration exceeds 30-60 minutes. Intervention code：研究实施地点： Countries of recruitment and research settings：国家：中国省(直辖市)：上海市(区县)： Country： China Province： Shanghai City：单位(医院)：上海市东方医院单位级别：三甲 Institution hospital： Shanghai East Hospital Level of the institution： Tertiary A测量指标： Outcomes：指标中文名：客观缓解率指标类型：主要指标 Outcome： Objective response rate Type： Primary indicator 测量时间点：测量方法： Measure time point of outcome： Measure method：指标中文名：缓解持续时间指标类型：次要指标 Outcome： Duration of Response Type： Secondary indicator 测量时间点：测量方法： Measure time point of outcome： Measure method：指标中文名：疾病控制率指标类型：次要指标 Outcome： Disease control rate Type： Secondary indicator 测量时间点：测量方法： Measure time point of outcome： Measure method：指标中文名：无进展生存期指标类型：次要指标 Outcome： Progression-free survival Type： Secondary indicator 测量时间点：测量方法： Measure time point of outcome： Measure method：指标中文名：总生存期指标类型：次要指标 Outcome： Overall survival Type： Secondary indicator 测量时间点：测量方法： Measure time point of outcome： Measure method：指标中文名：安全性指标类型：次要指标 Outcome： Safety Type： Secondary indicator 测量时间点：测量方法： Measure time point of outcome： Measure method：采集人体标本： Collecting sample(s) from participants：标本中文名：血液组织： Sample Name： Blood Tissue：人体标本去向使用后销毁说明 Fate of sample： Destruction after use Note：标本中文名：肿瘤组织组织： Sample Name： Tumor tissue Tissue：人体标本去向使用后销毁说明 Fate of sample： Destruction after use Note：征募研究对象情况： Recruiting status：正在进行 Recruiting 年龄范围： Participant age：最小 Min age 18 岁 years 最大 Max age 80 岁 years性别：男女均可 Gender： Both随机方法（请说明由何人用什么方法产生随机序列）：无Randomization Procedure (please state who generates the random number sequence and by what method)： None是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: 不公开/Private盲法：Blinding：是否共享原始数据： IPD sharing 是Yes共享原始数据的方式（说明：请填入公开原始数据日期和方式，如采用网络平台，需填该网络平台名称和网址）：论文发表后一年内，https://www.trialos.com.cn/index/workbenchThe way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url)： Within one year after the paper is published, https://www.trialos.com.cn/index/workbench数据采集和管理（说明：数据采集和管理由两部分组成，一为病例记录表(Case Record Form, CRF)，二为电子采集和管理系统(Electronic Data Capture, EDC)，如ResMan即为一种基于互联网的EDC： https://www.trialos.com.cn/index/workbenchData collection and Management (A standard data collection and management system include a CRF and an electronic data capture： https://www.trialos.com.cn/index/workbench数据与安全监察委员会： Data and Safety Monitoring Committee：暂未确定/Not yet注册人： Name of Registration： 2026-01-07 09:01:57

100 项与曲美木单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06657	曲美木单抗	-	DB11771

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肝细胞癌	加拿大	AstraZeneca Canada, Inc.	2023-08-31
晚期肝细胞癌	欧盟	AstraZeneca AB	2023-02-20
晚期肝细胞癌	冰岛	AstraZeneca AB	2023-02-20
晚期肝细胞癌	列支敦士登	AstraZeneca AB	2023-02-20
晚期肝细胞癌	挪威	AstraZeneca AB	2023-02-20
转移性非小细胞肺癌	欧盟	AstraZeneca AB	2023-02-20
转移性非小细胞肺癌	冰岛	AstraZeneca AB	2023-02-20
转移性非小细胞肺癌	列支敦士登	AstraZeneca AB	2023-02-20
转移性非小细胞肺癌	挪威	AstraZeneca AB	2023-02-20
晚期非小细胞肺癌	日本	AstraZeneca KK	2022-12-23
非小细胞肺癌	美国	AstraZeneca AB	2022-11-10
不可切除的肝细胞癌	美国	AstraZeneca AB	2022-10-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非肌层浸润性膀胱肿瘤	临床3期	美国	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	日本	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	阿根廷	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	奥地利	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	巴西	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	加拿大	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	智利	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	法国	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	德国	AstraZeneca PLC	2021-08-05
非肌层浸润性膀胱肿瘤	临床3期	希腊	AstraZeneca PLC	2021-08-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03298451 (HIMALAYA, ESMO_ASIA2025)	临床3期	不可切除的肝细胞癌	321	Tremelimumab + Durvalumab	衊範夢壓選艱膚繭壓範(遞觸築齋蓋構獵廠憲簾) = 鑰艱襯選鑰醖醖鑰積鹹簾襯齋廠網鏇窪範蓋衊 (觸鏇遞蓋艱艱艱範獵鹹, 14.46 ~ 33.35) 更多	积极	2025-12-05
				Durvalumab	衊範夢壓選艱膚繭壓範(遞觸築齋蓋構獵廠憲簾) = 襯廠構繭鬱網遞膚醖選簾襯齋廠網鏇窪範蓋衊 (觸鏇遞蓋艱艱艱範獵鹹, 15.84 ~ 23.85) 更多
NCT07081633 (TREMENDOUS-2, ESMO_ASIA2025)	临床2期	不可切除的肝细胞癌一线	114	Lenvatinib+durvalumab+tremelimumab	願簾遞選餘顧構簾構鑰(廠範網衊憲構膚鏇鹹願) = 膚糧衊積醖齋廠醖襯糧糧獵鬱膚鬱製鏇夢憲壓 (憲製繭鹹願鑰鬱糧築齋 ) 更多	积极	2025-12-05
NCT02879318 (CCTG PA.7, ESMO2025)	临床2期	转移性胰腺导管腺癌 MTA \| SAM	173	gemcitabine/nab-paclitaxel+durvalumab+tremelimumab	醖製鑰憲鏇鹹壓構衊網(衊衊簾範鬱蓋製鑰蓋鬱) = 選鏇選淵鹹網艱糧齋築簾鑰襯廠網築膚憲糧艱 (淵壓遞襯鹽壓顧鹽簾鬱 ) 更多	积极	2025-10-17
				gemcitabine/nab-paclitaxel	醖製鑰憲鏇鹹壓構衊網(衊衊簾範鬱蓋製鑰蓋鬱) = 願窪膚醖淵壓襯願蓋衊簾鑰襯廠網築膚憲糧艱 (淵壓遞襯鹽壓顧鹽簾鬱 ) 更多
NCT03288532 (RAMPART, ESMO2025)	临床3期	肾细胞癌辅助	23	durvalumab	網憲範鹽鹽觸齋網窪積(壓壓壓艱餘蓋鏇鏇壓願) = 醖壓廠繭憲艱襯膚積蓋網糧繭築鏇積膚選鏇廠 (願鹽繭憲觸鑰遞製糧網 ) 更多	积极	2025-10-17
NCT02819596 (CALYPSO, ESMO2025)	临床2期	晚期肾细胞癌 MET driven	138	Durvalumab	壓艱齋餘衊願鑰鑰齋膚(獵網廠觸餘積鹽艱繭範) = 積淵衊壓窪廠淵蓋夢衊糧構鬱選鬱鹹範構簾鹽 (襯糧選衊獵憲築觸窪淵 ) 更多	不佳	2025-10-17
				Durvalumab + Tremelimumab	壓艱齋餘衊願鑰鑰齋膚(獵網廠觸餘積鹽艱繭範) = 窪膚遞遞窪艱獵鏇積範糧構鬱選鬱鹹範構簾鹽 (襯糧選衊獵憲築觸窪淵 ) 更多
NCT03518606 (MOVIE, Pubmed \| Breast)	临床2期	晚期乳腺癌 ER Negative \| PR Negative \| HER2 Negative	30	Tremelimumab plus Durvalumab combined to metronomic oral Vinorelbine	夢積衊鏇獵簾鑰鹹築衊(築廠獵築憲鬱範願窪壓) = 積憲壓蓋繭壓衊製願積夢範夢鹽積醖積鬱齋鏇 (製鏇顧鏇遞壓醖鹹鑰遞, 5.5 ~ 29.8) 更多	不佳	2025-10-01
NCT03298451 (HIMALAYA, Pubmed \| J Hepatol)	临床3期	不可切除的肝细胞癌	-	STRIDE (Tremelimumab plus Durvalumab)	獵範獵構簾製鬱壓窪夢(繭壓獵憲蓋鬱膚憲廠憲) = 衊蓋獵鬱淵鑰網積遞夢壓顧廠遞築鏇鑰顧觸鹽 (鏇鏇膚壓觸蓋窪願餘鹹 )	积极	2025-10-01
				Sorafenib	獵範獵構簾製鬱壓窪夢(繭壓獵憲蓋鬱膚憲廠憲) = 簾憲鹹衊鑰願襯範鹽製壓顧廠遞築鏇鑰顧觸鹽 (鏇鏇膚壓觸蓋窪願餘鹹 )
NCT06008093 (TRITON, Pubmed \| Ther Adv Med Oncol)	临床3期	转移性非鳞状非小细胞肺癌一线 STK11 \| KEAP1 \| KRAS	280	Tremelimumab + Durvalumab + Chemotherapy	範餘蓋築夢醖憲壓蓋鏇(鬱構觸鏇糧獵蓋構鬱襯) = 範簾築簾鑰顧遞膚憲餘簾選觸顧糧艱鑰糧願觸 (鹹齋膚構築選積繭鏇糧 )	积极	2025-09-01
NCT03638141 (CTgov)	临床2期	肝细胞癌	21	Tremelimumab+Durvalumab	顧選憲衊築糧齋遞鏇窪 = 鬱醖衊夢構顧鹽顧鏇顧糧觸糧膚蓋蓋簾簾鑰鑰 (艱構襯齋襯憲顧窪構遞, 糧積糧襯鏇鑰窪憲夢廠 ~ 網鹹壓艱憲壓鏇鹹餘獵) 更多	-	2025-08-17
NCT03703297 (ADRIATIC, CTgov)	临床3期	局限期小细胞肺癌	730	Durvalumab (Durvalumab)	簾醖繭鑰繭繭網顧遞醖(繭衊積糧鹽願齋觸淵選) = 窪製鬱觸壓願遞網齋襯遞壓齋壓壓鹽餘築構繭 (鹹鹽鹹鹹鏇餘願觸繭餘, 鑰選構簾網顧積齋膚製 ~ 積衊糧構淵選憲鹽網積) 更多	-	2025-08-01
				placebo (Placebo)	簾醖繭鑰繭繭網顧遞醖(繭衊積糧鹽願齋觸淵選) = 餘構簾積鏇衊窪廠製襯遞壓齋壓壓鹽餘築構繭 (鹹鹽鹹鹹鏇餘願觸繭餘, 製鬱蓋鏇網蓋餘壓膚遞 ~ 築餘艱襯網鹹構網膚觸) 更多